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The transcription factor Nuclear Factor-erythroid 2-related-2 (Nrf2) controls cellular redox 
homeostasis and displays immunomodulatory properties. Nrf2 alters cytokine expression in 
murine T cells, but its effects in human T lymphocytes are unknown. This study investigated the 
expression and activity of Nrf2 in human activated CD4+ T helper lymphocytes (Th cells) that 
mediate the adaptive immune response. Th cells were isolated from peripheral blood 
mononuclear cells and activated with antibodies against CD3 and CD28, mimicking physiologic 
Th cell stimulation by dendritic cells. Nrf2 is hardly detectable in non-stimulated Th cells. 
Activation of Th cells rapidly and strongly increases the levels of Nrf2 protein by increasing 
NRF2 gene transcription. Th cell activation also enhances mRNA and protein levels of Nrf2 
target genes coding antioxidant enzymes. Blocking Nrf2 expression using chemical inhibitors or 
siRNAs prevents these gene inductions. Pre-treatment with inorganic arsenic, a Nrf2 inducer that 
does not alter NRF2 gene expression, increases protein level and transcriptional activity of Nrf2 
induced by Th cell stimulation. Inorganic arsenic enhances nuclear translocation of Nrf2, its 
interaction with the coactivator protein p300 and its DNA binding activity. Inhibition of Nrf2 
expression abrogates the effects of inorganic arsenic on mRNA levels of antioxidant genes, but 
does not alter the expression of IL-2, TNF-!, interferon- , and IL-17 in Th cells activated in the 
absence or presence of the metalloid. In conclusion, this study demonstrates for the first time that 
stimulation of human Th cells increases the transcription of NRF2 gene and the activity of Nrf2 
protein. However, modulation of Nrf2 levels does not modify the secretion of inflammatory 
cytokines from these T lymphocytes.   
Keywords: Nrf2, T lymphocytes, arsenic, antioxidant genes, cytokines. 
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 Nuclear factor-erythroid 2-related-2 (Nrf2) is a leucine zipper transcription factor that 
plays a central role in cellular responses to oxidative insults induced by chemicals, radiations and 
electrophilic stress [1]. Nrf2 controls basic and inducible expression of several antioxidant genes, 
such as NAD(P)H quinone oxidoreductase 1 (NQO1), heme oxygenase 1 (HMOX1), and 
modifier subunit for glutamate-cysteine ligase (GCLM) [1]. The NRF2 gene is expressed in most 
cell types and independently of inducers [1, 2]. Under basal conditions, Nrf2 is mainly 
sequestrated in the cytoplasm by the cytoskeleton-associated protein Kelch-like ECH-associated 
protein 1 (Keap1). Keap1 forms an E3 ubiquitin ligase complex with Cullin 3 and Ring-box 1, 
and triggers polyubiquitination of Nrf2 by promoting its binding to Cullin 3 [3]. Ubiquitinated 
Nrf2 is then degraded by the 26S proteasome with a half-life of approximately 20 min. 
Consequently, levels of Nrf2 protein are generally very low in basal state cells. Pro-oxidant 
chemicals classically increase intracellular Nrf2 levels through oxidation of thiol groups in 
pivotal cysteine residues of Keap1. Such oxidations probably cause conformational changes of 
the Keap1-E3 ubiquitin ligase complex that block Nrf2 ubiquitination and favor its 
accumulation. Nrf2 then rapidly translocates into the nucleus, dimerizes with the small Maf 
protein and binds to its antioxidant responsive elements (ARE) in gene promoters [2]. In nuclei, 
the coactivator CBP/p300 can cooperatively interact with specific domains of Nrf2 [3]. These 
interactions increase Nrf2 DNA binding and synergistically activate transcription of Nrf2 target 
genes [4]. A noncanonical mechanism of Nrf2 activation has recently emerged with the 
discovery that the Sesquestosome 1 (p62/SQSTM1) protein directly interacts with Keap1 at the 
Nrf2 binding sites [5].  When overexpressed, p62 can compete with the interaction between Nrf2 
and Keap1, resulting in accumulation and activation of Nrf2. 
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 Besides the control of intracellular redox status, Nrf2 also exerts a protective role towards 
several inflammatory disorders induced in murine models [6]. Using Nrf2 knockout mice, 
different groups have demonstrated that the loss of Nrf2 expression not only triggers oxidative 
damage, but also promotes the development of inflammation-related diseases, such as sepsis [7], 
atherosclerosis  [8], chronic obstructive pulmonary diseases [9, 10], asthma [11], chemical-
induced skin allergy [12], and autoimmunity [13]. Disruption of Nrf2 markedly increases the 
mortality of mice in response to endotoxin- and cecal ligation-induced septic shock [7]. 
Conversely, enhancement of Nrf2 expression by deleting Keap1 protein significantly reduces 
mortality, organ injury, and bacteremia [14]. In these murine models, the loss of Nrf2 increases 
the levels of inflammatory cytokines, chemokines, and adhesion molecules, suggesting that Nrf2 
can limit the development of inflammatory diseases by regulating the immune response [7, 8, 
13]. Analysis of immune cell function in Nrf2
-/-
 mice has revealed that inhibition of Nrf2 
expression alters the physiology of CD4+ T helper (Th) lymphocytes, which play a major role in 
the adaptive immunity [15]. Ex-vivo, activated Th cells from Nrf2
-/-
 mice exhibit a stronger 
ability to produce interferon-  (IFN- ) and tumor necrosis factor (TNF-!) [16]. This suggests 
that Nrf2 may thus repress the expression of major pro-inflammatory cytokines in murine T 
cells.  
The role of Nrf2 on redox homeostasis and immune gene expression in human activated T 
lymphocytes is widely unknown, in contrast to murine models. The present study was thus 
designed to determine firstly whether Nrf2 is expressed in human Th lymphocytes, and secondly 
whether Nrf2 can up-regulate antioxidant genes and repress genes encoding cytokines in these 
cells. Th cells are specifically activated by antigen-presenting cells, such as dendritic cells. Their 
optimal activation requires a double signal that involves engagement of the CD3-T cell receptor 
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(TCR) and stimulation of the CD28 receptor [17]. The present results demonstrate that, in vitro, 
stimulation of human Th lymphocytes either with monoclonal antibodies (Abs) directed against 
CD3 and CD28 proteins (aCD3/aCD28) that mimic the physiologic activation of Th cells [18], or 
with phorbol myristate acetate (PMA) in the absence or presence of ionomycin, strongly 
increases Nrf2 protein levels, likely through activation of NRF2 gene transcription. Th cell 
activation also markedly enhances, at both mRNA and protein levels, the Nrf2-dependent 
expression of several antioxidant genes, including that of NQO1, HMOX1, and GCLM genes. 
Interestingly, cell pre-treatment with inorganic arsenic (arsenite, As(III)), a reference post-
transcriptional Nrf2 inducer that also represses cytokine expression in activated human T 
lymphocytes [19, 20], primes costimulated Th cells for expression of these antioxidant genes. 
As(III) increases Nrf2 expression in activated Th cells and potently enhanced transcriptional 
activity of a Nrf2-driven luciferase reporter vector in activated leukemic T Jurkat cells. Genetic 
invalidation of Nrf2 markedly reduces the expression of both Nrf2 and antioxidant genes in 
human Th cells activated in the absence or presence of As(III). However, this loss of Nrf2 
neither prevents the induction of genes encoding cytokines nor their repression by As(III) in 
activated Th cells. 
 
Materials and Methods 
 
Chemical reagents and antibodies (Abs) 
As(III), tert-butylhydroquinone (tBHQ), phorbol myristate acetate (PMA), ionomycin, 
cycloheximide (CHX), MG132, actinomycin D, and N-acetylcysteine (NAC) were from Sigma-
Aldrich. BAY 11-7082 was purchased from Calbiochem. Primary Abs directed against Nrf2 (H-
300, sc-13032), p300 (C-20, sc-585), Hsc70, NQO1,  -GCS, and p38-kinase were from Santa 
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Cruz whereas HO-1 antibody was from Stressgene Biotechnologies. Ab against phospho-I"B! 
was purchased from Cell Signaling Technology. 
 
Cell culture 
To isolate human Th cells, peripheral blood mononuclear cells were first isolated from blood 
buffy coats from healthy donors through Ficoll gradient centrifugation. After separation of 
monocytes in a 1 h adhesion step, Th cells were purified from non-adherent cells by negative 
selection using Dynabeads T cell kits specific for human CD4+ cells (Invitrogen). The purity of 
the Th cell suspension was determined by flow cytometry (FC500, Beckman), using a 
monoclonal fluorescein isothiocyanate-conjugated Ab directed against human CD4 (Miltenyi) 
and the corresponding control isotype (IgG1) Ab. Analysis reveals that more than 93% of the 
selected cells were CD4-positive cells (Fig. S1). Cells were then cultured in RPMI 1640 
GlutaMAX medium (Gibco) supplemented with 10% fetal bovine serum, 100 IU/ml penicillin, 
and 100 µg/ml streptomycin. Cells were activated with Dynabeads coated with aCD3/aCD28 
(Invitrogen) (one bead per cell 1:1, or otherwise indicated). The leukemic T-cell line Jurkat was 
cultured in RPMI 1640 GlutaMAX medium supplemented with 10% fetal bovine serum, 2 mM 
glutamine, 100 IU/ml penicillin, and 100 µg/ml streptomycin in a 5% CO2 incubator at 37°C. 
 
 
Western blot analysis 
For whole cell lysates, cells were harvested and lysed for 20 min on ice in RIPA buffer 
supplemented with 1 mM phenylmethylsulfonyl fluoride, 0.5 mM dithiothreitol, 1 mM 
orthovanadate, and a cocktail of protein inhibitors (Roche). Cells were then
 
centrifugated at 
13000 × g for 15 min at 4°C. The resulting
 
supernatants were collected and frozen at !80°C or 
used immediately. For nuclear cell extracts, cells were lysed and nuclear proteins were prepared 
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using the Nuclear Extract Kit (Active Motif) according to the manufacturer’s instructions. 10 to 
30 µg of whole cell, cytoplasmic, or nuclear cell extracts were heated for 5 min at 100°C, loaded 
in a 4% stacking gel and then separated by a 10% sodium dodecyl sulfate polymerase gel 
electrophoresis (SDS-PAGE). Gels were electroblotted overnight onto nitrocellulose membranes 
(Bio-Rad). After blocking the membrane with a Tris-buffered saline (TBS) solution 
supplemented with 0.1% tween-20 and 5% bovine serum albumin, membranes were hybridized 
with primary Abs overnight at 4°C and incubated with appropriate horseradish peroxidase-
conjugated secondary Abs. For Nrf2 detection, membranes were first blocked with 5% skim milk 
in TBS and then hybridized overnight at 4°C with the H-300 Nrf2 Ab (1/1000) in TBS. 
Immunolabeled proteins were visualized by chemiluminescence. When indicated, a densitometry 
analysis was carried out to normalize the expression of each protein studied by that of p38-
kinase. Independent experiments were repeated at least three times. 
 
Immunoprecipitation
After treatment, Jurkat cells were collected, washed in cold PBS, and lysed for 30 min on ice in a 
buffer containing TBS pH 7.6, Triton X100 1%, 50 mM NaF, 1 mM phenylmethylsulfonyl 
fluoride, 1 mM sodium orthovanadate, and 1% protease inhibitor cocktail. Lysates were next 
centrifuged at 13000 × g for 5 min at 4°C and pre-cleared for 1 h at 4°C with 50 "l protein G–
Sepharose beads (GE Healthcare) to reduce nonspecific protein binding. Then, 1 mg of each 
sample was incubated overnight at 4°C in the presence of 2 "g anti-p300 Ab. The resulting 
immunocomplexes were next bound to Dynabeads
®
 Protein G (50 µl) for 4 h at 4°C. At the end 
of incubation, the beads were washed five times and heated at 100°C for 5 min. The samples 
were analyzed by a 10% SDS-PAGE and immunoblotted with Nrf2 and p300 Abs. Finally, a 
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densitometry analysis was carried out for each experiment to normalize the expression of Nrf2 to 
that of p300. Independent experiments were repeated four times. 
 
Total RNA isolation and real-time quantitative polymerase chain reaction (RT-qPCR). 
Total RNAs were extracted by the TRIzol method (Invitrogen) and then analyzed by RT-qPCR 
using the fluorescent dye SYBR Green methodology and an ABI Prism 7300 detector (Applied 
Biosystem), as previously described [19]. Specific gene primer sets were from Qiagen. Relative 
quantification of the steady-state target mRNA levels was calculated after normalization of the 
total amount of cDNA to a 18S RNA endogenous reference. Independent experiments were 
repeated at least three times. 
 
Transfection of siRNA 
Two sets of siRNAs from Dharmacon (Thermofischer) were used: control siRNAs (ON-
TARGETplus Non-targeting Pool) and NRF2 siRNAs (ON-TARGETplus SMART pool, L-
003755-00-0005). Transfection of siRNAs into Th cells was performed using the P3 Primary 
Cell 4D-Nucleofector™ X Kit (Lonza) with the Amaxa nucleofection technology. Briefly, ten 
million Th cells were incubated with 30 pmol of control or NRF2 SiRNAs and then 
electroporated, using the E0.115 program, on the 4D-Nucleofector™ System. After 24 h, the 
cells were washed and used for experiments. Independent experiments were repeated four times. 
Measurement of Nrf2 DNA binding 
Nrf2 DNA binding was analyzed using a specific ELISA-based TransAM™ kit from Active 
Motif. In brief, nuclear cell extracts (5 µg) were incubated for 1 h in a 96-well plate to which 
oligonucleotides, containing a Nrf2 consensus binding site, had been immobilized. After 
washing, the plate was incubated for 1 h with the primary Ab (TransAM Nrf2 kit, Active Motif, 
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1:1000), which specifically detected an epitope accessible only when Nrf2 is activated and bound 
to its cognate oligonucleotide. The plate was then washed and incubated with horseradish 
peroxidase-conjugated secondary Ab (1:1000) for 1 h at room temperature. Colorimetric readout 
was quantified by spectrophotometry at 450 nm. Independent experiments were repeated four 
times. 
 
Luciferase assays 
Jurkat cells (5 million) were electroporated with plasmids at 300V with one pulse of 10 ms using 
the BTM 830 electroporation generator (BTX Instrument Division, Holliston, MA) [21]. Cells 
were cotransfected with 10 µg of the NF-"B p65-driven luciferase reporter vector from 
Panomics or an Nrf2-driven luciferase reporter vector (a gift from Dr Ahn, Korea Institute of 
Radiological and Medical Sciences, Seoul, Korea), and 40 ng of a pRL CMV-Renilla reporter 
vector, used as an internal control. The Nrf2-driven luciferase reporter vector contains four 
repeats of the ARE consensus binding sequences (GCTGAGTCA) ligated in a pGL3 plasmid 
[22]. At 24 h after transfection, cells were pre-treated for 2 h with 20 µM As(III) or 50 µM tBHQ 
and then stimulated for 6 h with PMA or aCD3/aCD28. After treatment, cell extracts were 
assayed for luciferase activity with the Dual-Luciferase
®
 Reporter assay system from Promega, 
according to the manufacturer's instructions. Independent experiments were repeated at least four 
times. 
 
Measurement of intracellular production of reactive oxygen species (ROS) by flow cytometry 
Cells were stimulated with aCD3/aCD28 or PMA (20 ng/ml) for 2 h then incubated with the cell-
permeant 2',7'-dichlorodihydrofluorescein diacetate (H2-DCF-DA, 10 µM), an oxidation-
sensitive probe, for 30 min at 37°C. After treatment, cells were washed with PBS and analyzed 
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using a FC500 flow cytometer (Beckman Coulter). Fluorescence emission from oxidized H2-
DCF-DA was detected at 525 nm. Each measurement was conducted on 10000 events and 
analyzed using CXP analysis software. Two independent experiments were performed. 
 
Measurement of intracellular glutathione (GSH) 
Levels of intracellular GSH were quantified using the ThiolTracker™ Violet dye (Molecular 
probed, Invitrogen), which reacts actively with reduced thiols, and mainly with GSH, in intact 
cells. After treatments, cells were incubated with ThiolTracker™ Violet dye (10 µM) for 30 min 
at 37°C and then analyzed on a FACSAria cytometer (BD Biosciences) at 405 nm excitation. 
Each measurement was conducted on 10000 events and analyzed with CXP analysis software. 
Two independent experiments were performed. 
 
Quantification of cytokine levels  
Levels of IL-2, TNF-!, IFN- , and IL-17 secreted in culture medium were quantified by ELISA 
using specific Duoset ELISA development system kits (R&D Systems). Independent 
experiments were repeated four times. 
 
Statistical analysis.  
Data are expressed as means ± SD. Significant differences were evaluated using Student's t-test 
or the multi-range Dunnett’s test when multiple comparisons were studied. Criterion of 
significance of the difference between means was p< 0.05. 
 
Results
Activation of human Th cells potently increases Nrf2 expression 
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 First, to detect Nrf2 in Th cells, cells were treated for 6 h with 10 µM MG132, a 
proteasome inhibitor that blocks Nrf2 degradation. Using the H300 Nrf2 Ab from Santa Cruz, 
and whole cell lysates from MG132-treated Th cells, Nrf2 was detected as a single band at 
approx. 110 kDa on a 10% SDS-PAGE (Fig. 1A). This result is in accordance with the recent 
demonstration that the biological relevant species of Nrf2 migrate between average molecular 
weights of 95 kDa and 110 kDa [23]. Nrf2 was barely detectable in non-stimulated Th cells, but 
activation with aCD3/aCD28 (1:1) for 6 h induces its expression (Fig. 1A). In addition, kinetic 
analysis reveals that Nrf2 expression was increased by 2 h and is still measurable in cells 
stimulated for 24 h (Fig. 1B). Activation also regulates Nrf2 expression in a dose-dependent 
manner. Maximal induction was observed in cells stimulated with the ratio 1:1, aCD3/aCD28 at 
the lowest ratio used in this study (1:30) also slightly increased Nrf2 protein levels (Fig. 1C). In 
addition, Nrf2 expression was induced in Th cells activated with PMA and ionocymin, or PMA 
alone (Fig. 1D). This costimulation bypasses aCD3/aCD28-dependent engagement of the TCR, 
but activates the same downstream signaling pathways [24]. PMA also increased Nrf2 levels in 
the leukemic Jurkat T-cell line. In these activated cells, Nrf2 was weakly detectable in cytosol 
but strongly expressed in nuclear extracts (Fig. 1E). 
Up-regulation of Nrf2 expression in Th cells results from an increase of NRF2 mRNA levels 
 Nrf2 expression is commonly increased by post-transcriptional events that inhibit its 
degradation [1]. Particularly, ROS and pro-oxidant compounds can promote the dissociation of 
Nrf2 from the ubiquitin ligase complex through oxidation of thiol groups in Keap1, and can 
secondarily induce its translocation to the nucleus. Figure 2A indicates that NAC, a potent thiol 
reductive compound, did not inhibit the induction of Nrf2 expression in Th cells activated by 
aCD3/aCD28 or PMA (Fig. 2A). In addition, neither aCD3/aCD28 nor PMA increased ROS 
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levels in Th cells stimulated for 2 h (Fig. S2). By contrast, both aCD3/aCD28 and PMA rapidly 
and significantly increased mRNA levels of NRF2 gene in Th cells (Fig. 2B). Notably, NRF2 
mRNA levels were increased in Th cells activated for only 2 h. Moreover, the inhibition of 
NRF2 gene transcription by actinomycin D prevents expression of Nrf2 protein in activated Th 
cells. Figure 2C shows that addition of this inhibitor into culture medium, 2 h after the beginning 
of Th cell activation by aCD3/aCD28 or PMA, blocked the increase of Nrf2 protein levels 
detected at 6 h. Expression of the human NRF2 gene is positively regulated by NF-"B [25], a 
major transcription factor that controls several responses of activated Th cells and the production 
of many cytokines, such as IL-2 and TNF-! [26]. To test the involvement of NF-"B pathway in 
the induction of NRF2 gene expression, the I"B! inhibitor BAY 11-7082 was used [27]. At 5 
µM, this compound completely blocked the increase of I"B! phosphorylation (Fig. 2D) and the 
induction of IL2 and TNF-! mRNA levels, in activated Th cells (Fig. 2E). BAY 11-7082 also 
prevented the increase of both NRF2 mRNA and Nrf2 protein levels induced by aCD3/aCD28 
(Fig. 2F and 2G).  
Nrf2 protein controls the induction of antioxidant gene expression in activated Th cells 
 Nrf2 transcriptional activity was further investigated in activated Jurkat cells transfected 
with an Nrf2-luciferase reporter vector. Jurkat cell responsiveness to PMA and aCD3/aCD28 
stimulations was controlled for by quantifying the transcriptional activity of NF-"B. As 
previously described [28, 29], PMA induced the activity of a NF-"B p65-luciferase reporter 
vector in Jurkat cells (Fig. 3A). By contrast, costimulation with aCD3/aCD28 only slightly 
increased vector activity, which suggests that the TCR cannot be fully engaged by these Abs in 
these Jurkat cells. PMA also induced transcriptional activity of the Nrf2-luciferase reporter 
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vector. Although responsiveness of Jurkat cells to aCD3/aCD28 is low, this costimulation also 
significantly increased Nrf2-dependent luciferase activity (Fig. 3A), but this activity was lower 
than that induced by PMA. To better characterize Nrf2 activity, the effects of Th cell stimulation 
on the expression of various antioxidant genes classically up-regulated by this transcription 
factor were studied. Figure 3B demonstrates that aCD3/aCD28 or PMA significantly increased 
mRNA levels of GCLM and NQO1 genes in Th cells activated for 6 h or 24 h (Fig. 3B). If NRF2 
gene activation subsequently controls the induction of GCLM and NQO1 genes, inhibition of 
NRF2 mRNA translation should prevent expression of the two genes. In fact, the translation 
inhibitor CHX blocks the aCD3/aCD28-dependent expression of Nrf2 (Fig. S3), and this 
significantly reduced GCLM and NQO1 mRNA levels in aCD3/aCD28-costimulated Th cells 
(Fig. 3C). BAY 11-7082 also totally blocks expression of these genes (Fig. 3C). In addition, 
stimulation of Th cells with aCD3/aCD28 or PMA for 2 h, 6 h, and 24 h induces increased 
mRNA levels of the genes HMOX1 and TRX1, which encode heme oxygenase-1 and 
thioredoxin-1, respectively (Fig. S2). Similarly to the transcription of NQO1 and GCLM genes, 
transcription of HMOX1 and TRX1 genes is mainly controlled by Nrf2. To confirm that Nrf2 
actually controls up-regulation of these genes in activated human Th cells, the impact of genetic 
invalidation of Nrf2 by SiRNA technology was assessed. CTR and NRF2 SiRNAs were 
electroporated into Th cells using a 4D-Nucleofector™ System from Lonza. After 24 h of 
transfection, the cells were washed and costimulated for 6 h. Figure 3D demonstrates that NRF2 
SiRNAs decreased both NRF2 mRNA and Nrf2 protein levels in costimulated Th cells. Nrf2 
extinction also significantly reduced the up-regulation of mRNA levels of NQO1, GCLM, 
HMOX1, and TRX1 genes (Fig. 3D). Th cell activation is therefore likely to increase antioxidant 
gene expression by inducing the transcription of NRF2. 
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As(III) increases Nrf2-dependent expression of antioxidant genes in activated Th cells 
  A classical Nrf2 inducer that acts at a post-transcriptional level may be able to prime Th 
cells to express NRF2 and antioxidant genes in response to aCD3/aCD28 or PMA stimulation. 
Th cells were exposed to 2 µM As(III) for 2 h before stimulation; at this concentration, the 
metalloid does not alter the viability of activated Th cells [19] and, as expected, did not modulate 
NRF2 mRNA levels (Fig. 4A). However, As(III) significantly increased Nrf2 protein expression 
in non-stimulated (Fig. 4B) and aCD3/aCD28-stimulated Th cells (Fig. 4C). The metalloid also 
potently up-regulated mRNA levels of NQO1, GCLM, and HMOX1 genes induced by 
aCD3/aCD28 or PMA stimulation (Fig. 5A). In addition, As(III) significantly increased NQO1, 
 -glutamylcysteine synthase regulatory subunit ( -GCSm, coded by GCLM gene), and heme 
oxygenase-1 (HO-1) expression in Th cells costimulated with aCD3/aCD28 for 24 h (Fig. 5B). 
As  -GCS is a rate-limiting enzyme that controls the synthesis of glutathione (GSH) [30], 
intracellular amounts of this peptide were quantified by flow cytometry, using the fluorescent 
ThiolTracker violet dye. Figure S5 shows that, as previously reported [31], costimulation of Th 
cells with aCD3/aCD28 increases intracellular GSH levels. However, cell pre-treatment with 
As(III) did not further enhance the amounts of GSH in activated Th cells. This result can be 
explained by the fact that As(III) forms stable complexes with GSH, and thereby diminishes the 
level of reduced GSH being able to react with the ThiolTracker dye.  
 Given that inhibition of Nrf2 expression blocks the induction of antioxidant genes in 
activated Th cells, NRF2 gene repression might also prevent overexpression of these genes in 
cells pre-treated with As(III). Figure 6A clearly shows that BAY 11-7082 completely inhibits the 
increase of NQO1 and GCLM mRNA levels induced by the metalloid in aCD3/aCD28-
stimulated cells. In addition, genetic invalidation of Nrf2 also significantly reduced mRNA levels 
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of these two genes in metalloid-exposed cells (Fig. 6B). Altogether, these results support a major 
role for Nrf2 in As(III)-induced overexpression of antioxidant genes in activated Th cells. 
As(III) increases transcriptional activity of Nrf2 in Jurkat cells 
 To specify the molecular mechanisms by which As(III) can strengthen Nrf2-dependent 
expression of antioxidant genes, Nrf2 activity was analyzed in Jurkat cells activated with PMA, 
in the absence or presence of As(III). As shown in Figure 7A, pre-treatment of Jurkat cells with 
20 µM As(III) for 2 h significantly increased the levels of Nrf2 in nuclear extracts of PMA-
stimulated Jurkat cells. In nuclei, the coactivator p300 can associate with Nrf2 and promote its 
transcriptional activity. The results of coimmunoprecipitation experiments performed with p300 
Ab show that As(III) significantly increased physical interaction of p300 with Nrf2 in PMA-
activated Jurkat cells (Fig. 7B). In addition, the ELISA-based Nrf2 TransAM kit (Active Motif) 
showed that the metalloid significantly enhanced Nrf2 DNA binding in activated cells (Fig. 7C). 
Finally, As(III) augmented the Nrf2-dependent luciferase activity induced by PMA and 
aCD3/aCD28 in Jurkat cells (Fig. 7D); the metalloid also slightly increased luciferase activity in 
non-stimulated cells. 
The potent Nrf2 inducer tBHQ mimics the effects of As(III) towards antioxidant genes  
 Like As(III), tBHQ potently activates Nrf2 expression, at a post-transcriptional level, in 
several cell types [32]. Additional experiments were performed with this compound to confirm 
the priming of activated Th cells for antioxidant gene expression. As observed with As(III), 
tBHQ did not alter NRF2 mRNA levels (Fig. S6A) but it increased total Nrf2 levels in 
aCD3/aCD28-stimulated Th cells (Fig. S6B). Similarly, pre-treatment with tBHQ significantly 
up-regulated NQO1 and GCLM mRNA levels in Th cells stimulated with aCD3/aCD28 or PMA 
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(Fig. S6C). It also enhanced Nrf2-dependent luciferase activity in Jurkat cells stimulated with 
PMA or aCD3/aCD28 (Fig. S6D). 
Extinction of Nrf2 does not modify the expression of genes coding cytokines in Th cells 
 Besides its role on redox homeostasis, Nrf2 was shown to exert immunomodulatory 
effects in several murine models. The regulation by Nrf2 of the expression of immune-related 
genes in human Th cells activated with aCD3/aCD28 was examined. Costimulation increased 
mRNA levels of IL2, INFG, TNF, and IL17 genes in Th cells stimulated for 6 h (Fig. S7).  
However, genetic invalidation of Nrf2 expression with NRF2 SiRNAs did not alter the levels of 
mRNA of these four genes (Fig. 8A) or the levels of IL-2, TNF-!, IFN- # and IL-17 secreted in 
culture medium (Fig. 8B). We previously reported that cell pre-treatment with As(III) reduces 
the aCD3/aCD28-induced expression of IL-2, IFN- , and IL-17 [19, 20]. As(III)-dependent 
activation of Nrf2 could therefore mediate these inhibitory effects. The results show that the loss 
of Nrf2, in transfected Th with NRF2 SiRNA cells, does not inhibit the effects of the metalloid 
on IL2, TNF, IFNG, and IL17 genes in Th cells (Fig. 8A and 8B).  
 
Discussion
 The present study demonstrates that activation of human Th lymphocytes increases 
expression and activity of Nrf2, likely through the induction of NRF2 gene transcription. In 
addition, pre-treatment with electrophilic compounds that stabilize the Nrf2 protein primes Th 
cells for the expression of antioxidant genes. However, induction of NRF2 does not alter the 
expression of genes coding inflammatory cytokines in Th lymphocytes. 
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 The results demonstrate that Nrf2 protein expression is low and hardly detectable in non-
stimulated Th cells. This data was expected since, under basal conditions, Nrf2 is rapidly 
degraded by the proteasome in most cells. However, activation of human Th cells with 
aCD3/aCD28 or PMA + ionomycin strongly increases the level of Nrf2 protein. Classic 
regulation of Nrf2 expression occurs at a post-transcriptional level through oxidation of critical 
cysteine residues in Keap1 [1]. This mechanism is unlikely to occur in activated Th lymphocytes 
because NAC, a potent thiol reductive compound known to prevent oxidative stress-dependent 
activation of Nrf2 [33], does not block Nrf2 expression in activated Th cells; moreover, neither 
aCD3/aCD28 nor PMA increases the levels of ROS which markedly contribute to Keap1 
oxidation [2]. By contrast, activation of Th cells probably induces the transcription of NRF2 
gene. Indeed, the results demonstrate that activation of Th cells rapidly and significantly 
increases NRF2 mRNA levels with a kinetic very similar to that observed for Nrf2 protein 
expression. In addition, inhibition of gene transcription by actinomycin D, after the beginning of 
Th cell activation, totally blocks induction of Nrf2 protein expression. 
BAY 11-7082, a potent inhibitor of I"B!, also prevents Nrf2 expression. This result 
suggests that induction of NRF2 gene transcription can be mediated by the NF-"B transcription 
factor in activated Th cells. Two arguments support this idea: first, it has recently been 
demonstrated that the NF-"B subunits p50 and p65 control the inducible levels of NRF2 mRNAs 
in human acute myeloid leukemia cells through activation of a "B site in the promoter of NRF2 
gene [25]. Second, NF-"B activity is well-known to be rapidly and potently induced in T 
lymphocytes stimulated with aCD3/aCD28 or PMA [26, 29]. Indeed, TCR engagement by 
costimulation triggers several signaling pathways that notably activate the protein kinase C theta. 
Through activation of the I"B-kinase complex, this kinase increases the proteasome-dependent 
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degradation of phosphorylated-I"B! and allows the activation of NF-"B [26]. Stimulation of T 
lymphocytes with PMA mimics the effect of costimulation and also potently activates protein 
kinase C theta [26]. Although Nrf2 expression is not commonly induced at the transcriptional 
level, this mechanism of regulation was observed in other human immune cells. Activation of 
human macrophages by lipopolysaccharide, a bacterial endotoxin, up-regulates Nrf2 levels by a 
NF-"B-dependent signaling pathway that increases the amounts of NRF2 mRNAs [25]. 
Collectively, these results suggest that the immune response may result in the induction of Nrf2 
expression in key immune cells, including, at least, T lymphocytes and macrophages. 
 This study demonstrates that the induction of Nrf2 levels in Th cells is associated with 
the expression of several genes encoding antioxidant proteins. Costimulation of Th cells with 
aCD3/aCD28 notably increases the expression of NQO1, HMOX1 and GCLM genes at both 
mRNA and protein levels. Moreover, Th cell activation markedly stimulates GSH synthesis 
which is limited, in part, by transcription of the GCLM gene. Nrf2 is likely to control expression 
of these antioxidant genes in activated Th cells since i) aCD3/aCD28 and PMA increase Nrf2 
transcriptional activity and ii) pharmacological (by CHX and BAY 11-7082) and genetic (by 
NRF2 SiRNAs) inhibition of Nrf2 protein expression prevents the increase of NQO1 and GCLM 
mRNA levels. Consequently, the activation of Th lymphocytes may strengthen redox 
homeostasis by promoting Nrf2 expression and the subsequent induction of antioxidant genes. 
These regulations may thus constitute a general mechanism to prevent deleterious effects of 
electrophilic and pro-oxidant compounds in activated Th lymphocytes.  
 In this context, we previously reported that 2 µM As(III) induces the apoptosis/necrosis 
of human monocytes differentiating into macrophages or dendritic cells [34, 35], whereas it is 
non-cytotoxic, and unable to stimulate ROS production, in activated human Th cells [19]. The 
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present results show that pre-treatment with As(III) or tBHQ prime activated Th cells for 
expression of antioxidant genes by strengthening Nrf2 activation. Indeed, As(III) and tBHQ 
increase Nrf2 protein levels and potentiate Nrf2 transcriptional activity in PMA- and 
aCD3/aCD28-stimulated Jurkat cells. Moreover, inhibition of NRF2 expression blocks metalloid 
effects towards antioxidant genes. As(III) and tBHQ do not enhance the transcription of NRF2, 
but probably reduce the proteasome-dependent degradation of Nrf2 in Th cells. These two 
electrophilic compounds are thought to trigger Nrf2 stabilization through oxidations of critical 
thiol groups in Keap1, which diminish the affinity of Keap1 for Nrf2 [32, 36]. Recent studies 
demonstrate that the metalloid can also increase Nrf2 protein levels, either by impairing the 
Keap1-Cul3 E3 ubiquitin ligase complex activity or by inhibiting autophagic flux in a p62-
dependent manner [37, 38] .  
Experiments on Jurkat cells further specify the mechanism by which As(III) can enhance 
Nrf2 transcriptional activity. The metalloid increases nuclear concentrations of Nrf2, its 
interaction with the coactivator p300 and the DNA binding activity of Nrf2 in activated Jurkat 
cells. The coactivator p300 promotes transcription by acetylating core histones to decondensate 
chromatin and facilitate recruitment of the RNA polymerase machinery [4]. Also, p300 directly 
acetylates Nrf2 on lysine residues and thereby augments the binding of Nrf2 to specific AREs 
[39]. Altogether, these results show that optimal expression and activity of Nrf2 occur in human 
T cells when strong transcription of the NRF2 gene and stabilization of Nrf2 protein are 
simultaneously operant.  
 Studies on Nrf2 knockout mice have suggested that Nrf2 can modulate different functions 
of murine T lymphocytes, specifically their ability to express pro-inflammatory cytokines [16]. 
Activated Th cells from Nrf2 knockout mice secrete higher amounts of IFN-  and TNF-! than 
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their control counterparts from wild-type mice. The results of this study do not support a role for 
Nrf2 in the regulation of cytokine synthesis in human Th cells, since genetic invalidation of Nrf2 
expression does not up-regulate mRNA levels of IL2, IFNG, TNF, and IL17 genes in Th cells 
activated in the absence or presence of As(III). The different technologies used to repress Nrf2 
expression may explain the divergent results obtained with murine and human T cells. Indeed, 
the stable disruption of Nrf2 in Th cells from KO mice deeply affects cell homeostasis and may 
indirectly impair the expression of inflammatory genes in response to costimulation. Particularly, 
this loss of Nrf2 may stimulate the production of intracellular ROS at a level sufficient to 
increase both the aCD3/aCD28-dependent activity of NF-"B and the subsequent transcription of 
immune genes controlled by this transcription factor [6, 15]. Conversely, SiRNA-mediated 
repression of Nrf2 is transient and is unlikely to alter the global physiology of human Th cells. 
Thus, the silencing RNA technology allows the study of direct, rather than indirect, 
consequences of protein extinction. In this context, the present results suggest that Nrf2, 
expressed in activated human T lymphocytes, cannot directly interfere with the transcription of 
these immune genes. The fact that Nrf2 extinction does not prevent the repressive effects of 
As(III) on immune genes suggests that the modulation of Nrf2 levels may not constitute a 
promising therapeutic approach to limit or prevent the excessive T lymphocyte-derived 
production of inflammatory cytokines observed in chronic inflammatory diseases [40, 41].  
 In conclusion, this study demonstrates for the first time that costimulation of human Th 
lymphocytes up-regulates the expression and activity of Nrf2 at the transcriptional level. 
Induction of Nrf2 strengthens the redox status of Th cells, but does not impair their ability to 
express inflammatory cytokines.            
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Legends 
Figure 1. Activation of human T lymphocytes increases Nrf2 protein levels. Th cells were either 
untreated (NS) or stimulated for 6 h (A, C, D), or indicated times (B), with 10 µM MG132 (A), 
aCD3/aCD28 (A-D), or 20 ng/ml PMA + 0.5 µM ionomycin (iono) (D). In (E) Jurkat cells were 
stimulated with 20 ng/ml PMA for up to 4 h. Nrf2 protein expression in whole cell lysates (Th 
cells), cytosol and nuclear extracts (Jurkat cells) was analyzed by Western blot. In (B, C) 
densitometric analysis of Nrf2 expression is presented in the right panel and the results are 
expressed as means + SD of 5 (B) and 4 (C) independent experiments (*p<0.05, **p<0.01 versus 
“NS”). Equal gel loading was verified by re-probing nitrocellulose membrane with p38 kinase 
(A, B, C, D), Hsc70 or p300 (E) Abs. In (A, D, E), immunoblots are representative of at least 
three independent experiments. 
 
Figure 2. Up-regulation of Nrf2 protein results from an increase of NRF2 mRNA levels. Th cells 
were either untreated (NS) or pre-treated with 10 mM NAC or 5 µM BAY 11-7082 (Bay) for 2 h 
then left unstimulated or stimulated with aCD3/aCD28 or PMA for 1 h (D), 6 h (A, E, F, G) or 
the indicated times (B, C). In (C), 2 h after the start of cell stimulation, 3 µg/ml actinomycin D 
(Act) was added to the culture medium. Levels of Nrf2 (A, C, G) and phospho (p)-I"B! (D) in 
whole cell lysates were then analyzed by Western blot. Equal gel loading was verified by re-
probing nitrocellulose membrane with p38 kinase Ab. In (A) immunoblots are representative of 
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three independent experiments. In (C, D, G), densitometric analysis is presented in the right 
panel and the results are expressed as means + SD of four independent experiments. In (B, E, F), 
data are expressed relatively to mRNA levels found in NS Th cells, arbitrarily set at the value of 
1. Results are expressed as means + SD of at least four independent experiments. *p<0.05, 
*p<0.01 versus “NS”; #p<0.05, ##p<0.01 vs aCD3/aCD28 or PMA. 
Figure 3. Stimulation of T lymphocytes increases Nrf2 activity. In (A), Jurkat cells were 
transiently cotransfected for 24 h with a p65- or a Nrf2-driven luciferase reporter vector (10 µg) 
and a CMV-Renilla reporter vector (40 ng). Cells were left untreated (NS) or stimulated with 20 
ng/ml PMA or aCD3/aCD28 for 6 h. Luciferase activity was determined as indicated in 
“Materials and Methods”. In (B, C), Th cells were left untreated (NS) or pre-treated with 5 µg/ml 
CHX or 10 µM BAY 11-7082 (Bay) for 30 min or 2 h, respectively. In (D), Th cells were 
transiently transfected with CTR SiRNAs (Si CTR) of NRF2 SiRNAs (Si NRF2) for 24 h. Cells 
were then left untreated or stimulated with aCD3/aCD28 (B, C, D) or 20 ng/ml PMA (B) for 6 h 
(C, D) or the indicated times (B).  In (B, C, D), mRNA levels were determined by RT-qPCR 
assays. Data are expressed relatively to mRNA levels found in NS Th cells (B, C) or 
costimulated Th cells transfected with Si CTR (D), arbitrarily set at the value of 1. In (D), levels 
of Nrf2 and p38-kinase in transfected cells were analyzed by Western blot. (left bottom panels). 
The immunoblot is representative of three independent experiments. In (A, B, C, D), results are 
expressed as means + SD of at least four independent experiments. *p<0.05, **p<0.01, 
***p<0.001 versus “NS” (A, B, C), #p<0.05, ##p<0.01, ###p<0.001 versus “aCD3/aCD28” (C) 
or “Si CTR” (D).  
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Figure 4. As(III) increases Nrf2 protein levels in costimulated Th cells. Th cells were untreated 
(NS) or pre-treated with 2 µM As(III) for 2 h (A, B, C) and 8 h (B), then left unstimulated or 
stimulated with aCD3/aCD28 for 6 h. In (A), data are expressed relatively to mRNA levels found 
in NS Th cells, arbitrarily set at the value of 1.  In (B, C), Nrf2 expression was analyzed by 
Western blot. Equal gel loading was verified by re-probing nitrocellulose membrane with p38 
kinase Ab. In (B, C), densitometric analysis of Nrf2 expression is presented in the right panel. 
Results are expressed as means + SD of four independent experiments. *p<0.05, **p<0.01 
versus “NS”, #p<0.05 versus “aCD3/aCD28”. 
 
Figure 5. As(III) increases the expression of stress-related genes in costimulated Th cells. Th 
cells were either untreated (NS) or pre-treated with As(III) for 2 h. Cells were then left 
unstimulated or stimulated with aCD3/aCD28 or 20 ng/ml PMA for 6 h (A) or 24 h (B). In (A), 
data are expressed relatively to mRNA levels found in NS Th cells, arbitrarily set at the value of 
1.  In (B), protein expression was analyzed by Western blot. Equal gel loading was verified by 
re-probing nitrocellulose membrane with p38 kinase Ab. Densitometric analysis of protein 
expression is presented in the panel below the immunoblot. Results are expressed as means + SD 
of four independent experiments. *p<0.05, **p<0.01, ***p<0.001 versus “NS”,  #p<0.05, 
##p<0.01, ###p<0.001 versus “aCD3/aCD28” or “PMA”. 
 
Figure 6. Inhibition of Nrf2 expression prevents the effects of As(III) on NQO1 and GCLM 
gene in activated Th cells.  In (A), cells were either untreated or pre-treated for 2 h with 5 µM 
BAY 11-7082 and/or 2 µM As(III). In (B), cells were transfected for 24 h with CTR SiRNAs (Si 
CTR) or NRF2 SiRNAs (Si NRF2) and then, untreated, or pre-treated with 2 µM As(III) for 2 h. 
Next, Th cells were, non stimulated, or stimulated for 6 h with aCD3/aCD28. Data are expressed 
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relatively to mRNA levels found in NS Th cells (A) or costimulated Th cells transfected with Si 
CTR (not shown), arbitrarily set at the value of 1. Results are expressed as means + SD of four 
independent experiments. #p<0.05, ###p<0.001 versus “As(III) + aCD3/aCD28” (A) or “Si 
CTR” (B). 
 
Figure 7. As(III) enhances Nrf2 activity induced by Jurkat cell stimulation. Cells were either 
untreated (NS) or pre-treated for 2 h with 20 µM As(III) and then left unstimulated or stimulated 
with 20 ng/ml PMA or aCD3/aCD28 (D) for 2 h (A, B, C) or 6 h (D). After preparation of 
cytosol and nuclear extracts (A), or immunoprecipitation of p300 as described in Materials in 
Methods (B), Nrf2 protein present in cell extracts or bound to p300 was analyzed by Western 
blot, and quantified by densitometric analysis (A, right panel; B, bottom panel) Equal gel loading 
was verified by re-probing nitrocellulose membrane with Hsc70 and/or p300 Abs. In (C), DNA 
binding activity of Nrf2 protein, present in nuclear extracts of Jurkat cells, was determined using 
the ELISA-based Nrf2 TransAM kit from Active Motif. In (D), before pre-treatment, cells were 
transiently cotransfected for 24 h with a Nrf2-driven luciferase reporter vector (10 µg) and a 
CMV-Renilla reporter vector (40 ng). After stimulation, luciferase activity was determined as 
indicated in “Materials and Methods”. In (A, B, C, D), the results are expressed as means + SD 
of four independent experiments. ***p<0.001 versus NS; #p<0.05, ##p<0.01, ###p<0.001 versus 
“PMA” (A, B, C, D) or “aCD3/aCD28 (D).  
 
Figure 8. SiRNA-mediated invalidation of Nrf2 protein does not prevent expression of immune 
genes in Th cells activated in the absence or presence of As(III). Th cells were first transiently 
transfected for 24 h with CTR SiRNA (Si CTR) or NRF2 SiRNA (Si NRF2). Then, cells were 
either untreated or pre-treated with 2 µM As(III) for 2 h and left unstimulated or stimulated with 
31

aCD3/aCD28 for 6 h (A) or 24 h (B).  In (A), data are expressed relatively to mRNA levels 
found in stimulated Th cells transfected with Si CTR, arbitrarily set at the value of 1. In (B), the 
levels of cytokines secreted in culture medium were quantified by Elisa. Results are expressed as 
means + SD of four independent experiments. #p<0.05, ##p<0.01, ###p<0.001 versus activated 
Th cells non-exposed to As(III). 
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